(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Agenus (AGEN) on Tuesday swung to Q3 earnings of $0.72 per share from a loss of $0.28 per share a year earlier. Three analysts polled by Capital IQ...
(Updates with share price in second paragraph) Agenus (AGEN) said Friday that it is withdrawing its biologics license application for cervical cancer drug...
Agenus (AGEN) said Friday it is withdrawing its biologics license application for cervical cancer drug candidate balstilimab at the recommendation of the...
| Address | 3 Forbes Road Lexington, Massachusetts 02421-7305 |
| Phone | +1.781.674.4400 |
| Number of Employees | 294 |
| Recent SEC Filing | 01/06/2022 8-K |
| Chairman & Chief Executive Officer | Garo H. Armen |
| Chief Financial & Accounting Officer, VP-Finance | Christine M. Klaskin |
| Chief Technology Officer | Marc van Dijk |
| Chief Medical Officer | Steven O’Day |
| Price Open | $2.70 |
| Previous Close | $2.61 |
| 52 Week Range | $2.44 - 6.79 |
| Market Capitalization | $670.3 M |
| Shares Outstanding | 256.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/21/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.10 |
| Beta vs. S&P 500 | N/A |
| Revenue | $36.8 M |
| Net Profit Margin | 1.30% |
| Return on Equity | -3.00% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
